EGFR and non-small cell lung carcinoma: Gefitinib (ZD1839, Iressa) and erlotinib (OSI‐774, Tarceva) are small molecule EGFR TKIs that function by binding to their ATP‐binding pocket (Noble et al., 2004) and have been approved for NSCLC patients.